| YANCAV BRISTOL-MYERS SQUIBB COMPANY (A DELAWARE CORPORATION)
1735402 02 Jul 2015 | on 23 Jan 2019 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, respiratory diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use relating to metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents. | | | YANCAV BRISTOL-MYERS SQUIBB COMPANY
(A DELAWARE CORPORATION)
1445259 20 Jul 2009 | on 12 Aug 2015 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations relating to metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depresants, central nervous system stimulants, anti-psychotics and pharmaceutical antibodies. | |